Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia

Ultrasound in Obstetrics and Gynecology

Volumn 47, Issue 3, 2016, Pages 324-331

  Khalil, A ^a   Maiz, N ^b   Garcia Mandujano, R ^c   Penco, J M ^c   Nicolaides, K H ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

blood pressure; gestational hypertension; placental growth factor; pre eclampsia; pregnancy screening; soluble fms like tyrosine kinase 1

Indexed keywords

BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PGF PROTEIN, HUMAN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; BLOOD; EARLY DIAGNOSIS; FEMALE; GESTATIONAL AGE; HUMAN; LONGITUDINAL STUDY; MATERNAL HYPERTENSION; PREECLAMPSIA; PREGNANCY; PROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; SENSITIVITY AND SPECIFICITY;

ADULT; BIOMARKERS; EARLY DIAGNOSIS; FEMALE; GESTATIONAL AGE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; LONGITUDINAL STUDIES; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84959531761     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.15750     Document Type: Article

References (44)

1. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, Harper A, Hulbert D, Lucas S, McClure J, Millward-Sadler H, Neilson J, Nelson-Piercy C, Norman J, O'Herlihy C, Oates M, Shakespeare J, de Swiet M, Williamson C, Beale V, Knight M, Lennox C, Miller A, Parmar D, Rogers J, Springett A,. Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118 (Suppl 1) 1-203.
2. Duley L,. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-137.
3. World Health Organization. Make Every Mother and Child Count. World Health Report, 2005. Geneva, Switzerland: World Health Organization; 2005.
4. Bdolah Y, Sukhatme VP, Karumanchi SA,. Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights. Semin Nephrol 2004; 24: 548-556.
5. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA,. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
6. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA,. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
7. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H,. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206: 58. e1-e8.
8. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA,. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911-919.
9. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS,. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24: 1187-1207.
10. Sibiude J, Guibourdenche J, Dionne MD, Le Ray C, Anselem O, Serreau R, Goffinet F, Tsatsaris V,. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012; 7: e50208.
11. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, Simpson N, Waugh J, Anumba D, Kenny LC, Redman CW, Shennan AH,. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013; 128: 2121-2131.
12. Ohkuchi A, Hirashima C, Takahashi K, Suzuki H, Matsubara S, Suzuki M,. Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation. Hypertens Res 2013; 36: 1073-1080.
13. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH,. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 732-739.
14. Akolekar R, de Cruz J, Foidart JM, Munaut C, Nicolaides KH,. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenat Diagn 2010; 30: 191-197.
15. Kleinrouweler C, Wiegerinck M, Ris-Stalpers C, Bossuyt P, van der Post J, von Dadelszen P, Mol B, Pajkrt E, for the EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 2012; 119: 778-787.
16. Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH,. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation. Fetal Diagn Ther 2014; 35: 240-248.
17. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'Anna R,. Endoglin, PlGF and sflt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 837-842.
18. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV,. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008; 199: 266.e1-e6.
19. Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH,. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol 2008; 32: 871-876.
20. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA,. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23.
21. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, Mittal P, Mazaki-Tovi S, Than NG, Gomez R, Hassan SS,. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279-287.
22. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R,. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137-142.
23. Perni U, Sison C, Sharma V, Helseth G, Hawfield A, Suthanthiran M, August P,. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012; 59: 740-746.
24. Myatt L, Clifton RG, Roberts JM, Spong CY, Wapner RJ, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Sciscione A, Tolosa JE, Saade G, Sorokin Y, Anderson GD,; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG 2013; 120: 1183-1191.
25. Smith GC, Wear H,. The perinatal implications of angiogenic factors. Curr Opin Obstet Gynecol 2009; 21: 111-116.
26. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH,. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31: 66-74.
27. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM,. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV.
28. Rasbash J, Charlton C, Browne WJ, Healy M, Cameron B., (2009) MLwiN Version 2.1. Centre for Multilevel Modelling, University of Bristol.
29. Redman CWG,. Pre-eclampsia and the placenta. Placenta 1991; 12: 301-308.
30. Roberts JM, Redman CW,. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993; 341: 1447-1451.
31. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA,. Pathophysiology of hypertension during pre-eclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001; 38: 718-722.
32. Torry DS, Mukherjea D, Arroyo J, Torry RJ,. Expression and function of placenta growth factor: implications for abnormal placentation. J Soc Gynecol Investig 2003; 10: 178-188.
33. Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F, Foidart JM,. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 2008; 23: 1407-1415.
34. Roy H, Bhardwaj S, Yla-Herttuala S,. Biology of vascular endothelial growth factors. FEBS Lett 2006; 580: 2879-2887.
35. Kendall RL, Wang G, Thomas KA,. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226: 324-328.
36. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS,. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 1999; 13: 537-545.
37. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, Ahmed A,. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007; 115: 1789-1797.
38. Saad AF, Kechichian T, Yin H, Sbrana E, Longo M, Wen M, Tamayo E, Hankins GD, Saade GR, Costantine MM,. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci 2014; 21: 138-145.
39. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M,. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA 2011; 108: 1451-1455.
40. Ramma W, Ahmed A,. Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol 2014; 101-102: 153-160.
41. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH, Mallmann P, Stepan H, Karumanchi SA, Benzing T,. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124: 940-950.
42. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ,. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122: 478-487.
43. McElrath TF, Lim KH, Pare E, Rich-Edwards J, Pucci D, Troisi R, Parry S,. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012; 207: 407.e1-7.
44. Rizos D, Eleftheriades M, Karampas G, Rizou M, Haliassos A, Hassiakos D, Vitoratos N,. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study. Eur J Obstet Gynecol Reprod Biol 2013; 171: 225-230.